Survival Outcomes for Oral Cavity SCC at a Tertiary Centre in New Zealand
Josephine Stonyer, Final Year Medical Student/Trainee Intern, University of Auckland, New Zealand
Authors List
Introduction:
The management of oral cavity squamous cell carcinoma (OSCC) has changed over the years with more aggressive treatment approaches based on key risk factors, such as higher tumour staging, depth of invasion ≥3mm, poor differentiation, and the presence of perineural invasion. A key tenet of treatment, when indicated, includes post-operative radiotherapy, typically within 6 weeks. Literature reporting current survival outcomes for OSCC in a New Zealand context is scarce, thus the impact of these treatment developments in practice is not known.
Aims:
This study aims to provide updated tertiary institutional data on the survival of patients with OSCC in New Zealand. A secondary objective will establish the rate of delayed adjuvant radiation and its effects on outcome.
Methods:
A retrospective cohort study and survival analysis was performed between 2014 and 2021 to assess patients with OSCC. Data from new patients with OSCC treated with curative intent at Waikato Hospital, New Zealand, were analysed. Clinical staging was based on the American Joint Committee on Cancer Staging Manual, 8th edition. Outcomes were measured in overall survival (OS), disease specific survival (DSS), disease-free survival, and salvage rates for recurrences.
Results and Conclusions:
Survival analysis included 156 patients with OSCC. Average time between surgery and adjuvant radiation therapy was 64 days. OS and DSS were 80.1% and 85.0% respectively. Stage I and II OSCC had better survival compared to higher stages. 24 patients (15.4%) had disease recurrence with 21.7% remaining disease-free following salvage treatment. Survival outcomes for OSCC among New Zealanders have improved possibly due to advances in multidisciplinary care.
- Stonyer, J., Medical Programme, University of Auckland, Auckland, New Zealand
- Yap, M., Department of Oral and Maxillofacial Surgery, Waikato DHB, New Zealand
- Sanders, J., Department of Otolaryngology, Waikato DHB, New Zealand
- de Groot, C., Department of Radiation Oncology, Waikato DHB, New Zealand
- Singh, T., Department of Oral and Maxillofacial Surgery, Waikato DHB, New Zealand
Introduction:
The management of oral cavity squamous cell carcinoma (OSCC) has changed over the years with more aggressive treatment approaches based on key risk factors, such as higher tumour staging, depth of invasion ≥3mm, poor differentiation, and the presence of perineural invasion. A key tenet of treatment, when indicated, includes post-operative radiotherapy, typically within 6 weeks. Literature reporting current survival outcomes for OSCC in a New Zealand context is scarce, thus the impact of these treatment developments in practice is not known.
Aims:
This study aims to provide updated tertiary institutional data on the survival of patients with OSCC in New Zealand. A secondary objective will establish the rate of delayed adjuvant radiation and its effects on outcome.
Methods:
A retrospective cohort study and survival analysis was performed between 2014 and 2021 to assess patients with OSCC. Data from new patients with OSCC treated with curative intent at Waikato Hospital, New Zealand, were analysed. Clinical staging was based on the American Joint Committee on Cancer Staging Manual, 8th edition. Outcomes were measured in overall survival (OS), disease specific survival (DSS), disease-free survival, and salvage rates for recurrences.
Results and Conclusions:
Survival analysis included 156 patients with OSCC. Average time between surgery and adjuvant radiation therapy was 64 days. OS and DSS were 80.1% and 85.0% respectively. Stage I and II OSCC had better survival compared to higher stages. 24 patients (15.4%) had disease recurrence with 21.7% remaining disease-free following salvage treatment. Survival outcomes for OSCC among New Zealanders have improved possibly due to advances in multidisciplinary care.
